The COVID-19 vaccine developed jointly by Pfizer and BioNTech has been approved for 12 to 15-year-olds in the U.K, the Medicines and Healthcare products Regulatory Agency (MHRA) said on Friday. More than 2,000 children were involved in the clinical trial to determine the safety of the Pfizer-BioNTech vaccine, the chairman of the Commission on Human Medicines said. The MHRA said it would now be up to the U.K.’s Joint Committee on Vaccination and Immunisation (JCVI) to decide whether to vaccinate this age group as part of the country’s inoculation program. The European Medicines Agency approved the Pfizer-BioNTech shot for use in 12 to 15-year olds last week, while the U.S. Food and Drug Administration authorized the Pfizer-BioNTech vaccine for 12-to-15 year-olds on May 10.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
